GRI Bio Inc (NASDAQ: GRI) is a clinical-stage biopharmaceutical company developing oral small-molecule therapeutics targeting immune-mediated inflammatory diseases. The company generates no product revenue, funding operations through equity and debt financing. Its lead program, GRI-0621, is an oral therapy evaluated in a randomized, double-blind, multi-center Phase 2a clinical trial for idiopathic pulmonary fibrosis (IPF), enrolling 35 patients across treatment and placebo cohorts, of which 19 completed treatment in the treatment cohort and nine in the placebo cohort (as disclosed in the 10-K filed 2026-01-30). Research and development expenses are the primary cost driver, consisting of employee and consultant costs, contract research organization fees, contract manufacturing organization fees, and clinical and preclinical study costs tracked by product candidate. GRI-0621 represents the company's sole disclosed clinical-stage asset. The company has a license agreement with MEDICE Arzneimittel Putter GmbH & Co. KG, dated January 6, 2020, and completed a merger with Vallon in 2023.

Revenue model

No product revenue as of the fiscal year ended December 31, 2024. Operations are funded through equity offerings and debt financings, including securities purchase agreements with investors such as Altium Growth Fund, LP.

Products and services

GRI-0621: oral small-molecule product candidate evaluated in a Phase 2a clinical trial for idiopathic pulmonary fibrosis (IPF), assessing safety, tolerability, pharmacokinetics, and pharmacodynamic activity over 12 weeks of treatment (as of 10-K filed 2026-01-30).

Customers and end markets

No commercial customers as of fiscal year ended December 31, 2024. Target end market is patients with immune-mediated inflammatory diseases, specifically IPF. Prescribing physicians, hospitals, and third-party payors are identified as key gatekeepers for any future commercial product.

Value-chain role

Clinical-stage drug developer. Relies on contract research organizations, contract manufacturing organizations, and clinical sites for preclinical development, manufacturing, and clinical trial execution.

Geographic exposure

Multi-center clinical trial conducted across various centers; GDPR compliance obligations noted for EU data processing, indicating some clinical activity in the EU. Specific country-level breakdown not disclosed in the excerpts.

Source: SEC 10-K, filed 2026-01-30

Industry: Pharmaceutical Preparations Peers: CNBX Pharmaceuticals Inc Baudax Bio, Inc. Bespoke Extracts Inc APOLLO BioWellness Inc NEXIEN BIOPHARMA, INC. Johnson & Johnson